Status:
UNKNOWN
Safety and Efficacy of an Adult Acute Lymphoblastic Leukemia Chemotherapy for Adult Lymphoblastic Lymphoma
Lead Sponsor:
Centre Henri Becquerel
Conditions:
Lymphoblastic Lymphoma
Eligibility:
All Genders
18-59 years
Phase:
PHASE2
Brief Summary
The primary objective of this study is to evaluate the safety and the efficacy of an adult "acute lymphoblastic leukaemia" type chemotherapy in patients less than 60 years with lymphoblastic lymphoma....
Detailed Description
Lymphoblastic lymphomas (LL) are rare and represent less than 2% of the malignant non-Hodgkin lymphomas (NHL). The distinction between a LL and an acute lymphoblastic leukaemia (ALL) is difficult; it ...
Eligibility Criteria
Inclusion
- Patient with lymphoblastic lymphoma.
- Aged from 18 to 59 years.
- Medullary blasts rate less than 20%
- Non previously treated
- With or without central nervous system or meningeal involvement.
- No contra-indication to anthracyclines.
- No contra-indication to intensive treatments
- Negative HIV serology test
- Negative pregnancy test for all female patients of childbearing potential.
- Able to be regularly followed up.
Exclusion
- Evolutive cancer with the exception of non melanoma skin tumours or stage 0 (in situ) cervical carcinoma.
- Prior treatment with chemotherapy.
- Lymphoblastic Transformation of chronic myeloid leukaemia
- Patient unable to be regularly followed-up.
Key Trial Info
Start Date :
February 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2015
Estimated Enrollment :
155 Patients enrolled
Trial Details
Trial ID
NCT00195871
Start Date
February 1 2004
End Date
December 1 2015
Last Update
November 7 2013
Active Locations (19)
Enter a location and click search to find clinical trials sorted by distance.
1
Chr de La Citadelle
Liège, Belgium, 4000
2
Cliniques Universitaires U C L de Mont Godinne
Yvoir, Belgium, 5530
3
C H U D'Angers
Angers, France, 49033
4
Centre Hospitalier de La Region Annecienne
Annecy, France, 74011